Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials - Test2 - elhamkhani - TriplyDB

Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials

Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials

http://www.wikidata.org/entity/Q35211066

about

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned The prediagnostic phase of Parkinson's disease Rapid Eye Movement Sleep Behavior Disorder Symptoms Correlate with Domains of Cognitive Impairment in Parkinson's Disease.Epidemiology of Parkinson's disease.An update on the diagnosis and treatment of Parkinson disease Automated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity Neuroimaging in pre-motor Parkinson's disease Neurodegeneration and the Circadian Clock.Nicotine from cigarette smoking and diet and Parkinson disease: a review.MDS research criteria for prodromal Parkinson's disease.Lewy body dementias.Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder.Risk factors for probable REM sleep behavior disorder: A community-based study.The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease.Natural history of pure autonomic failure: A United States prospective cohort Personality and addictive behaviours in early Parkinson's disease and REM sleep behaviour disorder.Risk Factor Profile in Parkinson's Disease Subtype with REM Sleep Behavior Disorder.Recognition and treatment of autonomic disturbances in Parkinson's disease.The relevance of pre-motor symptoms in Parkinson's disease.Alterations in striato-thalamo-pallidal intrinsic functional connectivity as a prodrome of Parkinson's disease.The Concept of Prodromal Parkinson's Disease.Advances in Biomarker Research in Parkinson's Disease.Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases.Neuropathological basis of nonmotor manifestations of Parkinson's disease.Sleep Disturbances in the Prodromal Stage of Parkinson Disease.Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.Valproate-Associated Parkinsonism: A Critical Review of the Literature.Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder.Fifty years of Parkinson's disease: one step forwards, two steps back?Probable RBD and association with neurodegenerative disease markers: A population-based study.The relevance of gender in Parkinson's disease: a review.Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.Non-motor features of Parkinson disease.Outlining a Population "at Risk" of Parkinson's Disease: Evidence from a Case-Control Study.Insomnia and somnolence in idiopathic RBD: a prospective cohort study.Nonmotor symptoms and Parkinson disease in United States farmers and spouses.Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study.

P2860

Q26738357-899666F1-F241-46E7-9FEA-F21B477C2F59 Q26768732-CDA96B4C-7555-4BAC-B06F-6DE5C7F9B38D Q27302180-A4BAAC8F-1851-4964-B2D1-24AC5D85916E Q30238651-5AD458D3-7B6F-4BD1-8409-F544AADCF878 Q30243899-8330322D-C84E-4875-A9C1-EF78C8421636 Q30356478-3A372438-3580-4593-91EE-A5AEC053AB8E Q30846938-0259FC82-6A10-448B-8149-34FDB0BE393F Q33676222-FD16A531-72E9-4944-B60D-3F9A8ECA10A1 Q33736479-2946E442-630F-4DB2-9BB8-2E4BFFD9442C Q33862534-96D3260F-C9ED-41C9-AD50-D37D142A123B Q34498279-0C3ACD00-F685-4EB0-9F2A-BAE760F2AD83 Q34502646-B35C4B06-87D6-43A7-8992-9B596164C981 Q36300054-D18F39FD-1F67-4729-816F-D929AD1DE35F Q36782900-C812709D-1171-4526-815A-E52449A94A03 Q36968317-7C00D688-B1CF-4C98-AF40-9328F99A422E Q37104904-396FE77A-A4AD-4FCC-9875-0EF749956926 Q37662455-1D407E84-75E1-4A37-9AD7-F87A4A518940 Q37737516-2ED3D85D-AB72-4B72-A45D-7D81E23C8922 Q38395832-6EACCAF0-6736-4800-ABCD-F001C023EA7C Q38594855-6E3B59E0-4B43-49E6-A829-2BE10EA49114 Q38594857-F34E86BA-F1D5-4780-9B5C-EBCCD3FCC9CA Q38601317-D000E481-8068-4458-8BAF-2F9DE99BBF58 Q38612230-695D69ED-7F09-4E6C-A4AC-7D06ED2E069A Q38681599-81E30F6B-3E41-4DE4-8531-740E9E3887B7 Q38741342-C280101E-4E59-4021-8DDC-7CCDCBCD0ABE Q38794098-FB67DCCC-5814-4B0B-B5CD-BEADB1C177AF Q38807628-69B509B0-E459-48E5-9A26-40A58C9187C9 Q38827153-B9655AD2-5AB5-49C8-8BF5-54DA0557B8CF Q38851844-7D05F12E-0B4D-4C36-A4FE-2ED3C2D6180A Q38858537-4CB42694-65DB-4888-B26E-F5F55FF314AA Q38886330-67146B83-EA67-43DE-969A-EDBF7842E447 Q38977064-35BFB7BD-36B3-4FD6-9C6D-5F3BF48B7A4C Q38981556-7F43FACE-3AC4-4598-8C01-9F5327977B08 Q39039214-53558CA5-ACCB-4545-A9D2-04B347672A92 Q39149219-52A99E48-6E11-4179-BB93-E86F4649596C Q39358549-9E6D7221-BA97-4312-ACEE-ACB50EBEB236 Q40406670-399177F3-77AE-4AF7-BD0E-BFDEC084CDFD Q42138798-3BA2B7B8-CD17-451C-A6C6-3CA80E6470C9 Q42365204-615A2C40-096C-4CC3-8537-C046D86DCEAC Q44953314-E072DD98-D74F-4A9F-A4A9-4039F23BFDDC

P2860

Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials

http://www.wikidata.org/entity/Q35211066

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@ast

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@en

type

label

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@ast

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@en

prefLabel

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@ast

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@en

P1433

Q35211066-3BF71090-0549-4B70-979F-AA74BD88768E

P1476

Q35211066-CC061215-AA81-43F6-A894-CA16B174EAB7

P2093

Q35211066-4D983E1E-E21C-44DA-8062-E7A4870456E8

Q35211066-613B9E10-4892-4C7F-AE35-FDD2038A9DFB

Q35211066-6D38938A-C582-411C-910A-80DDF264BB4C

Q35211066-79577FDC-0807-4047-83A1-3F0C360AECBF

Q35211066-98372C40-3AD2-4283-89F4-9675E1739FFF

P2860

Q35211066-07687C12-0716-45B6-BB8F-BB5B043DD62C

Q35211066-1156DE93-13F0-4769-AF99-F08649E1E756

Q35211066-144511EE-88AB-4E56-8C7E-6DE866BEE68F

Q35211066-17469E0E-0722-4E97-B1EE-1BA7B4CDAE63

Q35211066-1CD7929D-217A-40C2-AE28-6DB8CD97CCB2

Q35211066-2520230C-504F-4356-85C1-58F2CF6C6439

Q35211066-2ACB0F6D-DFC8-43AD-806E-1169DE4D66CB

Q35211066-33A51EB3-34BC-4772-AAE6-F7AF919D5FD1

Q35211066-3562CB75-7AF6-465A-8A81-902B4014BAD6

Q35211066-37FC8DB4-1D8E-4F87-AD39-C0146708C316

P304

Q35211066-2F3CEE6E-110D-49F1-9FBB-FCA6078AD180

P31

Q35211066-3979516D-F3F8-4452-8E4F-D570E71F3452

P356

Q35211066-66D8582C-D862-4129-B44B-51BC8C0248E4

P407

Q35211066-4107DE4F-9A0B-41B5-89F0-23FDC4CDBAAA

P433

Q35211066-B15771DF-DE92-40F3-8C87-57F58F0B9489

P478

Q35211066-CA947446-2D6A-481B-BA36-9D9B1EE36AB6

P577

Q35211066-B4B36C71-018C-44E2-8196-E3258EE47BF2

P698

Q35211066-89A940D6-8D8F-42F2-BC23-B84F69988478

P921

Q35211066-94E378FD-DF1C-4397-BFF3-890D3672C214

P932

Q35211066-B66A738B-A86F-459E-9C84-AF328E158C52

P356

WNL.0000000000001364

P1433

P1476

Parkinson risk in idiopathic R ...... ing for neuroprotective trials

@en

P2093

Daphné Génier Marchand

http://www.w3.org/2001/XMLSchema#string

Jacques Y Montplaisir

http://www.w3.org/2001/XMLSchema#string

Jean-Francois Gagnon

http://www.w3.org/2001/XMLSchema#string

Josie-Anne Bertrand

http://www.w3.org/2001/XMLSchema#string

Ronald B Postuma

http://www.w3.org/2001/XMLSchema#string

P2860

An Inventory for Measuring Depression

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder.

What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.

Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease.

Clinical practice. Mild cognitive impairment.

A systematic method for clinical description and classification of personality variants. A proposal.

Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study.

Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study.

P304

1104-1113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000001364

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25681454

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4371408

http://www.w3.org/2001/XMLSchema#string